CryoLife seeks partner for FibRX:
This article was originally published in Clinica
CryoLife is now free to discuss partnerships and license agreements for its fibrin-based bioadhesive, FibRX. In March, Bayer paid CryoLife $250,000 for exclusive rights to negotiate a licence, but no agreement was made (see Clinica No 699, p 13). CryoLife, which is based in Atlanta, Georgia, plans to apply for FDA approval to begin human trials for FibRX in the second quarter of 1997.